当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2012年第5期 > 正文
编号:12191219
瑞舒伐他汀对PCI患者术后脂联素和高敏C反应蛋白的影响(3)
http://www.100md.com 2012年2月15日 邹勇 杨天伦 蒲晓群 李传昶 谢启应 徐细平
第1页

    参见附件(2920KB,3页)。

     [7] Kumada M,Kihara S,Sumitsuji S,et al. Association of hypoadiponectinemia with coronary artery disease in men [J]. Arterioscler ThrombVase Biol,2003,23(1):85-89.

    [8] Pischon T,Girman C,Hotamisligil GS,et al. Plasma adiponectin levels and risk of myocardial infarction in men [J]. JAMA,2004,291(14):1730-1737.

    [9] Ouchi N,Kihara S,Arita Y,et al. Adipocyte-derived plasma protein,adiponectin,suppresses lipid accumulation and class a scavenger receptor expression in human monocyte-derived macrophages [J]. Circulation,2001,103(8):1057-1063.

    [10] 郭华涛,王雁先.瑞舒伐他汀对PCI患者血清炎性因子影响的研究[J].中国热带医学,2011,11(5):615-617.

    [11] 郝晓燕,田建会,赵晖.瑞舒伐他汀对稳定型心绞痛PCI病人炎症因子影响[J].青岛大学医学院学报,2010,46(4):312-314.

    [12] Crisby M,Nordin FG,Shah PK,et al. Pravastatin treatment increases collagen content and decreases lipid content,inflammation,metalloproteinases,and cell death in human carotid plaques [J]. Circulation,2001,103(7):926-933.

    [13] Kinlay S,Timms T,Clark M,et al. Comparison of effect of intensive lipid lowering with Atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia [J]. Am J Cardiol,2002,89(10):1205-1207.

    (收稿日期:2011-09-15 本文编辑:张瑜杰)

您现在查看是摘要介绍页,详见PDF附件(2920KB,3页)